Discussion between 1oldprof, SLC, Peteman and

New Post Public Reply Private Reply Replies (0) Message Board
someconcerns someconcerns #35152
293
Discussion between 1oldprof, SLC, Peteman and frroll:

Quote:
1oldprof Saturday, 06/24/17 02:18:32 PM
Re: cabel post# 187185
Post # of 187257

If I am looking at the correct chemical structure of Brilacidin, I disagree with your assertion. A peptide bond is formed by the joining of a carboxyl group and an amino group. I see 4 of these in Brilacidin. The key for B is that they are not in series, thus it is not a polypeptide per se but it does have peptide bonds thus...peptidic.


Quote:
slcimmuno Member Level Saturday, 06/24/17 02:22:54 PM
Re: 1oldprof post# 187239
Post # of 187257

Good to see you posting
I'm no PhD but my read of the "Nonpeptidic" claim to Brilacidin and the other HDP-Ms is that they are polymers (synthetic) and thus not real peptides ... mimetic of that are more stable, selective and potent -- designed to be better than what even Ma Nature made -- like the $6million dollar man. My 02c.


Quote:
1oldprof Saturday, 06/24/17 02:32:46 PM
Re: slcimmuno post# 187240
Post # of 187257

Non polypeptide would be more accurate. It has peptide bonds in it. Dr Zasloff may have been referring to these. It is NOT a protein and that is what is key IMO. I am not an organic or biochemist by trade but I used to know my way around this stuff....but I am happy to admit my error if it is so. But before sending messages to mgt, I just thought you would want to know this


Quote:
1oldprof Saturday, 06/24/17 02:36:47 PM
Re: slcimmuno post# 187240
Post # of 187257

And "polymer" does not refer to synthetic compounds strictly in the resesrch world. There are synthetic polymers, but many many polymeric compounds that are found in nature


Quote:
slcimmuno Member Level Saturday, 06/24/17 02:38:37 PM
Re: 1oldprof post# 187241
Post # of 187258

Googled one of the old Polymedix decks -- this might give you some more context / insight into the "non-peptidic" usage, history of the HDP-Ms pre IPIX

Feel free to share any thoughts

http://files.shareholder.com/downloads/ABEA-4...l_Peptides


Quote:
slcimmuno Member Level Saturday, 06/24/17 02:38:37 PM
Re: 1oldprof post# 187241
Post # of 187258

Googled one of the old Polymedix decks -- this might give you some more context / insight into the "non-peptidic" usage, history of the HDP-Ms pre IPIX

Feel free to share any thoughts

http://files.shareholder.com/downloads/ABEA-4...l_Peptides


Quote:
1oldprof Saturday, 06/24/17 03:05:05 PM
Re: slcimmuno post# 187243
Post # of 187258

Thanks for that! I had done some reading previous to investing. Honestly, I think they meant "non-protein" as non-peptidic. I wouldn't know what Zasloff was referring to with peptidic, just conjecturing. From my perspective, "non proteinaceous" would have been much less ambiguous.


Quote:
frrol Member Level Saturday, 06/24/17 03:14:05 PM
Re: 1oldprof post# 187241
Post # of 187258

Thanks all for this discussion. It appears there is some grey area in the scientific terminology, which can explain the 'opposing' assertions. I think we got some clarity today.


Quote:
frrol Member Level Saturday, 06/24/17 03:17:00 PM
Re: slcimmuno post# 187240
Post # of 187258

Perhaps it also improves the oral bioavailability of B through the digestive tract. Not sure.


Quote:
1oldprof Saturday, 06/24/17 03:24:49 PM
Re: petemantx post# 187245
Post # of 187258

Hey Pete, I was working on a floor above on something else. In retrospect, what I was working on was central to inflammatory processes and has been invaluable. But researchers talk at the water cooler too and went to a bunch of talks on p53 and what was cutting edge AT THE TIME. I used to consider p53 a pipe dream. But not so much anymore. Honestly, the poster by "independent researchers" had some really fascinating findings on the Western blots, some not what I would have expected and points to a, surprise surprise, much more complex system than a simple linear relationship. The planned genetic expression work which the researchers alluded to is, hopefully, going to crystallize this more. Yes, I think that p53 and some of the recent successes in clarification will spawn a whole new approach to cancer IMO. From a research standpoint, and a BP standpoint, mAbs were much easier to approach and faster to get a product on the market. Was it the best approach? Too lengthy to message. I think you will see a multi pronged approach to cancer and the research will bear that out. p53 is here to stay.

Btw, "independent researchers" has got to refer to Bologna and I, for one, am stoked to see that this has not fizzled away. Would love to see MD Anderson too, maybe in time


Quote:
georgejjl Saturday, 06/24/17 03:27:44 PM
Re: 1oldprof post# 187163
Post # of 187258

Imagine Prurisol as an oral drug for treating psoriasis, psoriatic athritis, rheumatoid arthritis, etc. and Brilacidin as a topical treatment for the same conditions.

Good luck and GOD bless,

George


Quote:
1oldprof Saturday, 06/24/17 03:29:56 PM
Re: petemantx post# 187245
Post # of 187258

To answer a little further, I think Kevetrin and the other compound being developed by that private firm, name escapes me, has been a shot across the bow and has led to a lot more visibility


Quote:
1oldprof Saturday, 06/24/17 03:33:29 PM
Re: georgejjl post# 187252
Post # of 187258

If they could get B in an oral formulation and if they show modulation of IL17, the two together would be HUGE! If B orally turns into an issue, there are many routes to try. Topical would be interesting!


Quote:
slcimmuno Member Level Saturday, 06/24/17 04:44:30 PM
Re: frrol post# 187249
Post # of 187258

Have been some good Convos today on the Science if you can manage to avoid the lightweight Bunk.

Bodacious Brilacidin is Bankable imo.

Already compared favorably as a single-dose to 7-day Dapto, a Bn+ in ABSSSI, and now its coming thru strong as a topical in OM and IBD. That there is negligible systemic absorption but high efficacy suggests its profile as a topical should remain rather benign... as it works its Host Defense wonders.

Re formulation and delivery, IPIX seems quite confident they can turn it into foam/gel and pill. That would be huge for GI -- UC and Crohns. The biologics, with their bad side effects, are mediocre here so lots of room for B to enter. Think B as a drug that is as good as or better than them ... similar to Prurisol for PsO.

DeGrado and his group deserve a lot of credit for designing B but IPIX does too: finding a tarnished but real (not fake) diamond in the rough and polishing it up, particularly as to its anti-inflammatory properties.

Brilacidin's moment to shine fast approaching... IBD OM DERM on top of ABX. And there are more areas beyond that.

Big Pharma always says they want a Platform drug, well B is showing signs of becoming exactly that...

If the oppty presents, I say sell Prurisol and put the $$$ back into B ... rightly formulated it has Multiple Blockbusters written already over it. Kevetrin could follow a similar path -- formulate it as an Oral to leverage its PK, then test it across multiple areas.

Exciting times ahead.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vietnam Pushes Tech Boundaries with VGC v1.0 Chip

Updated Category News Views 98

How often do you hear about a country stepping confidently into the tech realm with its own set of silicon-built security? This is exactly what's happening with Vietnam's ambitious leap with the VGC v1.0 chip, rolled out by the nation's Government Cipher Committee and Viettel Group. Hitting a level of speed that blows past the sluggish pace of software-only methods, this...

Continue Reading
Africa-Caribbean Trade Potential: A $1.65B Opportunity

Updated Category News Views 49

Untapped Opportunities Between Africa and the Caribbean Who's ready to shake up the trade game between Africa and the Caribbean? According to a fresh-off-the-press report from the International Trade Centre (ITC) and Afreximbank, we could be looking at a whopping $1.65 billion in annual trade between these two regions by 2030. That's right, a billion with a 'B'. But let...

Continue Reading
Tea Extract Market Expansion: $4.7B by 2031 Forecast

Updated Category News Views 105

The Surging Demand for Tea Extracts The tea extract market's carving out quite a niche for itself. From $3.22 billion in 2026, it's primed to scale up to a cool $4.70 billion by 2031. That's a steady 7.9% growth rate, and it's just fueled by the booming demand for all things natural and health-oriented. Natural and Functional: Key Industry Drivers Consumers these days...

Continue Reading
Choosing Lakefront Flooring: A Practical Guide for Owners

Updated Category News Views 0

Understanding Lakefront Challenges Owning a lakefront rental sounds like a dream, right? But the reality involves a mixed bag of conditions that can chew up flooring faster than a pair of puppy claws on exposed oak. We're talking about moisture, sand, and constant guest traffic making these properties a hot mess if you're not careful. Waterproof Vinyl: The Smart Bet...

Continue Reading
PG&E, Edison Push Liability Cap Amid Firestorm

Updated Category News Views 176

The Thanksgiving Playbook Nobody Wanted Sacramento's corridors are buzzing with electric tension. And why? It's not some trivial turkey drama but a simmering scandal over two utility giants trying to sneak a liability cap into law faster than you can ask for a second slice of pumpkin pie. PG&E and Edison have a little secret—a covert strategy to limit shareholder...

Continue Reading
Bascom's $30.8M Vegas Refi Amid Market Hurdles

Updated Category News Views 58

Diving into the Vegas Real Estate Scene Alright, folks, let's roll up our sleeves and talk about something that's got my attention—Bascom Group's recent $30.8 million refinance of the Gateway Villas Apartments in Las Vegas. This ain't just another vanilla transaction in the back pages of some real estate journal. It's a play that screams strategy, especially in a world...

Continue Reading
ZBS Group Takes Over Rabinowitz’s CPA Practice with Bold Moves

Updated Category News Views 467

Transitioning Power in the CPA World Let's cut to the chase—when a seasoned CPA like Joseph Rabinowitz picks up the phone to secure a succession partner, it's a big deal. Enter ZBS Group LLP, steered by Michael Zaidman, which isn't a stranger to these waters, undertaking their fourth CPA practice acquisition through Rabinowitz's corner of the accounting universe....

Continue Reading
Zeelo Strengthens West Coast Expansion with Zoss Hire

Updated Category News Views 107

Zeelo's got itself a new captain steering its West Coast ship, and it’s none other than transportation whiz Gillian Zoss. Now, when a company like Zeelo pulls a move like this, it's worth taking a moment to chew over the implications. Zeelo's been known for shaking up how folks think about moving people—employees, kids to schools, you name it—their model's rattled a...

Continue Reading
AI Shift: From Tech Marvels to Practical Uses

Updated Category News Views 80

A New Chapter in the AI Narrative Take a seat, folks, because we're watching AI swing from showy tech to something as plain as plumbing infrastructure. Imagine models that once cost bundles per token now going for peanuts. We're talking a nosedive from $37.50 to a mere 18 cents. It’s a seismic shift, steering the conversation from 'Are they the best models?' to 'How...

Continue Reading
Segway Powersports Charges Ahead with MY27, iFUN 2.0

Updated Category News Views 32

Rolling Out Power and Tech at EICMA 2026 A real gearhead's delight rolled out at EICMA 2026, with Segway Powersports lighting up the stage showcasing their 2027 upgrades. If you're betting on somewhere as time-honored for two- and four-wheeling wonders as EICMA, you know stakes get real high. Segway's making noise with their MY27 lineup and a next-gen iFUN 2.0, aiming to...

Continue Reading

Top 5 Most Recently Viewed Articles

AVID Products Chooses Walt & Company for Strategic PR Partnership

Updated Category News Views 163

Power Play: What This Partnership Means Now, let’s chew on this collaboration. AVID is an old hat in the audio game, flaunting over 70 years of experience. They’re not new to the block and neither is Walt & Company, whose forte lies in tech PR. The timing of this union screams opportunity as AVID gears up to expand its reach. The pressure's on here; tech markets are...

Continue Reading
Exploring Sustainable Finance: A New Path for U.S. Businesses

Updated Category News Views 178

Introduction to Sustainable Finance in the United States The UN Global Compact Network USA has released a compelling report emphasizing the critical role of the U.S. private sector in championing sustainability through innovative financial strategies. Titled "Driving Progress: Sustainable Finance for the Advancement of the Sustainable Development Goals (SDGs)," the report...

Continue Reading
PSI Services to Enhance Insurance Licensing in New Partnership

Updated Category News Views 167

PSI Services Partners with Insurance Department for Licensing Exams PSI Services, a leading force in licensure testing, has been chosen by the New Hampshire Insurance Department as the new partner for administering insurance licensing examinations. Effective from a future date, PSI will leverage its innovative testing solutions to provide candidates with a comprehensive...

Continue Reading
How Institutional Investors Are Preparing for 2025 Market Dynamics

Updated Category News Views 526

Optimism Amid Uncertainty: Institutional Investors' Perspective Institutional investors are approaching the upcoming year with cautious optimism, as indicated by recent survey findings from Natixis Investment Managers. This sentiment emerges from the recognition of both favorable market conditions as well as significant global economic challenges. Geopolitical Concerns...

Continue Reading
Zumiez Inc. Reports Positive Growth in Fiscal Q3 2024

Updated Category News Views 176

Strong Performance in Fiscal Q3 2024 Growth in Comparable Sales and Earnings Zumiez Inc. (NASDAQ: ZUMZ) has showcased impressive results for its third quarter, reflecting positive growth in comparable sales which rose by 7.5% compared to the previous year. Gross margins also demonstrated a robust increase, rising by 140 basis points to 35.2%. This marks a significant...

Continue Reading